Bayesian joint models for multi-regional clinical trials

被引:0
|
作者
Bean, Nathan W. [1 ]
Ibrahim, Joseph G. [1 ]
Psioda, Matthew A. [1 ]
机构
[1] Univ N Carolina, Dept Biostat, Chapel Hill, NC 27514 USA
关键词
Bayesian clinical trials; Bayesian model averaging; Joint models; Laplace approximation; LEADER trial; Multi-regional clinical trials; SURVIVAL-DATA; APPROXIMATION;
D O I
10.1093/biostatistics/kxad023
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
In recent years, multi-regional clinical trials (MRCTs) have increased in popularity in the pharmaceutical industry due to their ability to accelerate the global drug development process. To address potential challenges with MRCTs, the International Council for Harmonisation released the E17 guidance document which suggests the use of statistical methods that utilize information borrowing across regions if regional sample sizes are small. We develop an approach that allows for information borrowing via Bayesian model averaging in the context of a joint analysis of survival and longitudinal data from MRCTs. In this novel application of joint models to MRCTs, we use Laplace's method to integrate over subject-specific random effects and to approximate posterior distributions for region-specific treatment effects on the time-to-event outcome. Through simulation studies, we demonstrate that the joint modeling approach can result in an increased rejection rate when testing the global treatment effect compared with methods that analyze survival data alone. We then apply the proposed approach to data from a cardiovascular outcomes MRCT.
引用
收藏
页码:852 / 866
页数:15
相关论文
共 50 条
  • [31] A NOTE ON MULTI-REGIONAL MARKETING
    INGENE, CA
    PARRY, ME
    MANAGEMENT SCIENCE, 1995, 41 (07) : 1194 - 1201
  • [32] MULTI-REGIONAL MIGRATION OF LABOR
    BRENNAN, MJ
    ECONOMETRICA, 1963, 31 (03) : 582 - 582
  • [33] Practical issues and lessons learned from multi-regional clinical trials via case examples: a Japanese perspective
    Ando, Yuki
    Hamasaki, Toshimitsu
    PHARMACEUTICAL STATISTICS, 2010, 9 (03) : 190 - 200
  • [34] Trial design issues and treatment effect modeling in multi-regional schizophrenia trials
    Chen, Yeh-Fong
    Wang, Sue-Jane
    Khin, Ni A.
    Hung, H. M. James
    Laughren, Thomas P.
    PHARMACEUTICAL STATISTICS, 2010, 9 (03) : 217 - 229
  • [35] Lessons Learned From Multi-regional Trials With Signals of Treatment Effect Heterogeneity
    Li, Gang
    Quan, Hui
    Lan, Gordon
    Ouyang, Soo Peter
    Chen, Fei
    Robieson, Weining
    Wang, William
    Binkowitz, Bruce
    Yuan, Shuai Sammy
    Tanaka, Yoko
    Chen, Josh
    Matsuoka, Nobushige
    Zhang, Lanju
    Yang, Song
    Gallo, Paul
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2020, 54 (01) : 21 - 31
  • [36] Lessons Learned From Multi-regional Trials With Signals of Treatment Effect Heterogeneity
    Gang Li
    Hui Quan
    Gordon Lan
    Soo Peter Ouyang
    Fei Chen
    Weining Robieson
    William Wang
    Bruce Binkowitz
    Shuai Sammy Yuan
    Yoko Tanaka
    Josh Chen
    Nobushige Matsuoka
    Lanju Zhang
    Song Yang
    Paul Gallo
    Therapeutic Innovation & Regulatory Science, 2020, 54 : 21 - 31
  • [37] A New Vision of Classical Multi-regional Input-Output Models
    Halkos, George E.
    Tsilika, Kyriaki D.
    COMPUTATIONAL ECONOMICS, 2018, 51 (03) : 571 - 594
  • [38] Bayesian models for subgroup analysis in clinical trials
    Jones, Hayley E.
    Ohlssen, David I.
    Neuenschwander, Beat
    Racine, Amy
    Branson, Michael
    CLINICAL TRIALS, 2011, 8 (02) : 129 - 143
  • [39] Establishing consistency across all regions in a multi-regional clinical trial
    Tsou, Hsiao-Hui
    Hung, H. M. James
    Chen, Yue-Ming
    Huang, Wong-Shian
    Chang, Wan-jung
    Hsiao, Chin-Fu
    PHARMACEUTICAL STATISTICS, 2012, 11 (04) : 295 - 299
  • [40] Bayesian design of clinical trials using joint models for longitudinal and time-to-event data
    Xu, Jiawei
    Psioda, Matthew A.
    Ibrahim, Joseph G.
    BIOSTATISTICS, 2022, 23 (02) : 591 - 608